{
  "release_id": "f6f6f1b6f50379ed",
  "id": "cardio:rocket-af",
  "owner": "cardio",
  "kind": "study",
  "slug": "rocket-af",
  "name": "ROCKET AF",
  "aliases": [],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "A large trial that compared the blood thinner rivaroxaban with warfarin in people with non-valvular atrial fibrillation at increased risk of stroke. Rivaroxaban was shown to be no worse than warfarin at preventing stroke or a clot elsewhere in the body. It was not shown to be better in the analysis of everyone randomized, and the overall rate of major bleeding was similar.",
  "summary_technical": "ClinicalTrials.gov NCT00403767, a phase 3, randomized, double-blind, parallel-group, non-inferiority study sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., with Bayer as collaborator, completed 2010-09. The main report is Patel et al. 2011;365(10):883-91 (abstract read only; the journal is on the cited PubMed record). The registry start date (2006-12) carries no actual-or-estimated type. Enrollment differs by source: the registry gives 14269 and the abstract says 14,264 patients were randomly assigned; the difference is not explained and not reconciled. The registry marks the results-first-posted date ESTIMATED, so no date type is recorded for it. No structured findings are recorded here; the numbers are on the claim.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-10-15",
  "last_evidence_check": "2026-10-14",
  "next_review_due": null,
  "identifiers": [
    {
      "scheme": "nct",
      "value": "NCT00403767",
      "normalized_value": "NCT00403767",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "system": [
        "heart"
      ],
      "condition-area": [
        "arrhythmias",
        "stroke"
      ]
    }
  },
  "payload": {
    "design": "Randomized, double-blind, parallel-group, non-inferiority trial (registry: allocation randomized, parallel model, masking quadruple, primary purpose prevention). The abstract says the primary analysis was per-protocol and as-treated.",
    "drug_phase": "3",
    "registry_statuses": [
      {
        "status": "COMPLETED",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      }
    ],
    "start_date": {
      "date": "2006-12",
      "type": null,
      "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
    },
    "primary_completion_date": {
      "date": "2010-09",
      "type": "actual",
      "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
    },
    "completion_date": {
      "date": "2010-09",
      "type": "actual",
      "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
    },
    "results_first_posted": {
      "date": "2012-07-17",
      "type": null,
      "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
    },
    "countries": [
      {
        "code": "US",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "AR",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "AU",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "AT",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "BE",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "BR",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "BG",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "CA",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "CL",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "CN",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "CO",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "CZ",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "DK",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "FI",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "FR",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "DE",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "GR",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "HU",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "IN",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "IL",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "LT",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "MY",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "MX",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "NL",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "NZ",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "NO",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "PE",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "PH",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "PL",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "RO",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "RU",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "SG",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "ZA",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "KR",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "ES",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "SE",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "CH",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "TW",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "TH",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "UA",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "GB",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "VE",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "HK",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "code": "TR",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      }
    ],
    "care_setting": null,
    "stopped_early": null,
    "enrollment": [
      {
        "count": 14269,
        "basis": "enrolled",
        "unit": "participants",
        "snapshot": "cardio:ctgov-nct00403767-2026-10-14"
      },
      {
        "count": 14264,
        "basis": "randomized",
        "unit": "patients",
        "snapshot": "cardio:pubmed-21830957-2026-10-14"
      }
    ],
    "arms": [
      {
        "id": "cardio:rocket-af-arm-rivaroxaban",
        "label": "Rivaroxaban",
        "intervention": "cardio:rivaroxaban",
        "description": "Rivaroxaban at a daily dose of 20 mg (abstract). The registry lists one 20 mg tablet once daily, with a dose adaptation to 15 mg once daily for moderate renal impairment, and a matching warfarin placebo."
      },
      {
        "id": "cardio:rocket-af-arm-warfarin",
        "label": "Warfarin",
        "intervention": null,
        "description": "Dose-adjusted warfarin (abstract), with a matching rivaroxaban placebo (registry). No separate entity is recorded for warfarin."
      }
    ],
    "findings": []
  },
  "content_digest": "2c0f3237a56f94fdec0131a8848c184c5f06d04c9ad89e18e862f4fbd65edd7b",
  "review": {
    "content_digest": "2c0f3237a56f94fdec0131a8848c184c5f06d04c9ad89e18e862f4fbd65edd7b",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "investigates",
        "label": "Tests rivaroxaban against warfarin",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:rivaroxaban",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:ctgov-nct00403767-2026-10-14",
          "locator": "protocolSection.armsInterventionsModule.interventions[0].name"
        },
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "investigates",
        "label": "Lists atrial fibrillation as its first condition",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:atrial-fibrillation",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:ctgov-nct00403767-2026-10-14",
          "locator": "protocolSection.conditionsModule.conditions[0]"
        },
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "sponsored_by",
        "label": "Collaborator on the registry record",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:bayer",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:ctgov-nct00403767-2026-10-14",
          "locator": "protocolSection.sponsorCollaboratorsModule.collaborators[0].name"
        },
        "primary": false,
        "role": "collaborator",
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": []
  },
  "page_path": "studies/rocket-af/",
  "context_path": "api/v1/context/cardio--rocket-af.md"
}